Winton Group’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $997K | Buy |
+9,555
| New | +$997K | 0.05% | 437 |
|
|
2024
Q3 | – | Sell |
-8,823
| Closed | -$710K | – | 624 |
|
|
2024
Q2 | $710K | Buy |
8,823
+5,385
| +157% | +$433K | 0.05% | 380 |
|
|
2024
Q1 | $274K | Buy |
+3,438
| New | +$274K | 0.02% | 536 |
|
|
2023
Q3 | – | Sell |
-5,179
| Closed | -$372K | – | 771 |
|
|
2023
Q2 | $372K | Sell |
5,179
-7,655
| -60% | -$550K | 0.03% | 441 |
|
|
2023
Q1 | $792K | Buy |
12,834
+328
| +3% | +$20.2K | 0.05% | 528 |
|
|
2022
Q4 | $965K | Sell |
12,506
-1,456
| -10% | -$112K | 0.06% | 417 |
|
|
2022
Q3 | $623K | Sell |
13,962
-3,847
| -22% | -$172K | 0.04% | 575 |
|
|
2022
Q2 | $682K | Buy |
17,809
+1,465
| +9% | +$56.1K | 0.04% | 611 |
|
|
2022
Q1 | $676K | Buy |
16,344
+2,335
| +17% | +$96.6K | 0.04% | 593 |
|
|
2021
Q4 | $529K | Buy |
14,009
+4,309
| +44% | +$163K | 0.03% | 664 |
|
|
2021
Q3 | $320K | Sell |
9,700
-3,072
| -24% | -$101K | 0.02% | 1064 |
|
|
2021
Q2 | $862K | Buy |
12,772
+2,111
| +20% | +$142K | 0.05% | 608 |
|
|
2021
Q1 | $604K | Buy |
10,661
+3,901
| +58% | +$221K | 0.03% | 773 |
|
|
2020
Q4 | $551K | Sell |
6,760
-23,082
| -77% | -$1.88M | 0.04% | 742 |
|
|
2020
Q3 | $2.13M | Buy |
29,842
+1,807
| +6% | +$129K | 0.07% | 497 |
|
|
2020
Q2 | $2.31M | Sell |
28,035
-1,254
| -4% | -$103K | 0.06% | 585 |
|
|
2020
Q1 | $1.72M | Sell |
29,289
-198,237
| -87% | -$11.7M | 0.05% | 623 |
|
|
2019
Q4 | $23.5M | Buy |
+227,526
| New | +$23.5M | 0.33% | 28 |
|